Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey

References

• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054
   PubMed Web of Science ®Google Scholar
• Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57:1920-59
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91:1123-5
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-32
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (2009). Summary of product characteristics: Efient. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000984/WC500021971.pdf. [Last accessed 2009]
   Google Scholar
• Wiviott SD, Desai N, Murphy SA, et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011;108:905-11
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010;122:394-403
   PubMed Web of Science ®Google Scholar
• Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010;121:71-9
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Graham JB, Bae JP, et al. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ 2012;15:166-74
   PubMedGoogle Scholar
• Organisation for Economic Cooperation and Developement (OECD): Purchsing power parities. http://stats oecd org/Index aspx?datasetcode=SNA_TABLE4. [Last accessed 3 January 2012]
   Google Scholar
• Organisation for Economic Cooperation and Developement (OECD): Consumer Price Indices. http://stats oecd org/Index aspx?datasetcode=MEI_PRICES. [Last accessed 3 January 2012].
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modeling for health economic evaluation. Oxford: Oxford University Press, 2006
   Google Scholar
• Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008;26:799-806
   PubMed Web of Science ®Google Scholar
• Armitage P. Statistical methods in medical research. 2nd edn. Oxford: Blackwell Scientific, 1987
   Google Scholar
• Collett D. Modelling survival data in medical research. London: Chapman and Hall/CRC, 1994
   Google Scholar
• Sterbetafel Deutschland, 2005/2007. Wiesbaden: Statistisches Bundesamt, 2008. Ref Type: Report
   Google Scholar
• Statistics Netherlands. The Hague, Netherlands (2009). Netherlands Life tables. www.cbs.nl. [Last accessed 2009]
   Google Scholar
• Statistics Sweden. Stockholm, Sweden (2007). Sweden Life tables. www.scb.se. [Last accessed 2009]
   Google Scholar
• TURKSTAT. Life Tables. Ankara: Statistical Institute, 2008
   Google Scholar
• Government Actuary's Department. Interim Life Tables, United Kingdom 2006-2008. London: GAD, 2009. http://www.gad.gov.uk/Demography%20Data/Life%20Tables/index.html. [Last accessed November 2009]
   Google Scholar
• Rosengren A, Wilhelmsen L, Hagman M, et al. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Goteborg, Sweden. J Intern Med 1998;244:495-505
   PubMed Web of Science ®Google Scholar
• Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005;293:2908-17
   PubMed Web of Science ®Google Scholar
• Allen LA, O'Donnell CJ, Camargo CA, Jr et al. Comparison of long-term mortality across the spectrum of acute coronary syndromes. Am Heart J 2006;151:1065-71
   PubMed Web of Science ®Google Scholar
• Mueller HS, Forman SA, Menegus MA, et al. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. J Am Coll Cardiol 1995;26:900-7
   Google Scholar
• Taneja AK, Collinson J, Flather MD, et al. Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). Eur Heart J 2004;25:2013-8
   PubMed Web of Science ®Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Centre for Health Economics Discussion Paper 172. University of York, York, UK, 1999
   Google Scholar
• Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20
   PubMed Web of Science ®Google Scholar
• Wechowski J, Woehl A, Tetlow T, et al. Cost-utility analysis in the UK settling off vasoactive drug treatments in acute bleeding oesophageal varices in cirrhotic patients - a discrete event simulation model. Value Health 2009;9:A190
   Google Scholar
• Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata. College Station, TX: Stata Press, 2005
   Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008;26:733-44
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE, 2008
   Google Scholar
• World Health Organisation. CHOosing Interventions that are Cost Effective (WHO-CHOICE). 1998. http://www.who.int/choice/costs/CER_thresholds/en/index.html. [Last accessed January 2013]
   Google Scholar
• Montalescot G, Sideris G, Cohen R, et al. Prasugrel 10 mg provides greater platelet inhibition than clopidogrel 900/150 mg in UA/NSTEMI ACS - the ACAPULCO study. Eur Heart J 2008;29(Suppl):746
   Google Scholar
• Assessment report for Efient. European Medicines Agency Doc Ref: EMEA/117561/2009 2009
   Google Scholar
• Hochholzer W, Wiviott SD, Antman EM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011;123:2681-9
   PubMed Web of Science ®Google Scholar
• IQWIG. General methods for the assessment of the relation of benefits to costs. Cologne: Institute for Quality and Efficiency in Health Care, 2009.
   Google Scholar
• TLV. General guidelines for economic evaluations from the Pharmaceutical Benefits Board. Stockholm: Pharmaceutical Benefits Board, 2003.
   Google Scholar
• CVZ. Guidelines for Pharmacoeconomic Research in the Netherlands. Rotterdam: College voor zorgverzekeringen, Diemen, 2006.
   Google Scholar
• Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making choices in health: WHO Guide to cost-effectiveness analysis. Geneva: WHO, 2003.
   Google Scholar